Thomas Köhnke

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

Sascha Haubner, Fabiana Perna, Thomas Köhnke et al. · Leukemia · 2018 · 328 citations · Full text

Medicine, Hematology, Oncology +17

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

Christina Krupka, Peter Kufer, Roman Kischel et al. · Leukemia · 2015 · 249 citations

Life Sciences, Immunology, Oncology +16

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel et al. · Blood · 2013 · 207 citations

Life Sciences, Immunology, Molecular Biology +17

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Haijiao Zhang, Yusuke Nakauchi, Thomas Köhnke et al. · Nature Cancer · 2020 · 203 citations · Full text

Medicine, Hematology, Oncology +16

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

Thomas Köhnke, Christina Krupka, Johanna Tischer et al. · Journal of Hematology & Oncology · 2015 · 176 citations · Full text

Life Sciences, Immunology, Oncology +17